2022-502408-57-00招募中3 期
PEACE-6 Poor Responders: A randomized phase III trial evaluating the efficacy and safety of 177Lu-PSMA-617 in addition to Standard of Care (SoC) versus SoC alone in de novo metastatic hormone-sensitive prostate cancer (mHSPC) patients having a serum PSA level of ≥ 0.2 ng/mL at 6 to 8 months after systemic treatment initiation for mHSPC.
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
- Unicancer
- 入组人数
- 300
- 试验地点
- 24
- 主要终点
- Overall Survival (OS) is defined as the time from the date of randomization to the date of death due to any cause. Patients still alive at time of the analysis will be censored at the date of last news.
研究概览
简要总结
Efficacy of 177Lu-PSMA-617 administered on top of the ongoing standard systemic treatment in patients with de novo mHSPC presenting with a serum PSA level of ≥ 0.2 ng/mL at 6 to 8 months after systemic treatment initiation for mHSPC compared to standard systemic treatment alone in terms of Overall Survival (OS) and radiographic Progression-Free Survival (rPFS).
入排标准
- 年龄范围
- 18 years 至 65+ years（65+ Years, 18-64 Years）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Signed a written informed consent form prior to any trial specific procedures Note: In case of physical incapacitation, a trusted representative of their choice, which is not the Investigator or sponsor, can sign on the behalf of the patients.
- •Stable or declining PSA level but not a rising one
- •Serum PSA of ≥ 0.2 ng/mL at 6 to 8 months after ADT initiation
- •Testosterone level < 50 ng/dl or < 1.7 nmol/L
- •Be fit enough for 177Lu-PSMA-617 treatment: • Adequate bone marrow function: hemoglobin ≥ 90 g/L (in absence of red blood cell transfusion within 4 weeks prior to randomization), absolute neutrophil count ≥ 1.5 x109/L, platelet count >100 x109/L • Adequate liver function: aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.0 x upper limit of normal (ULN), or ≤ 5.0 x ULN in the presence of liver metastases; bilirubin < 1.5 x ULN (unless known or suspected Gilbert syndrome, then < 3 x ULN is permitted) • Adequate renal function: calculated creatinine clearance ≥ 50 ml/min (using the MDRD or CKD EPI method)
- •For sexually active men with female partners of reproductive potential or with pregnant women, agreement to use a condom with another effective contraceptive method during trial participation and up to 14 weeks after study treatment completion.
- •Affiliated to the social security system or in possession of equivalent private health insurance (according to local regulations for participation in clinical trials).
- •Willing and able to comply with the protocol for the duration of the trial including undergoing treatment and scheduled visits, and examinations including follow-up.
- •Aged ≥ 18 years old
- •Life expectancy > 6 months as per investigator estimate
- •ECOG performance status ≤ 2
- •Men with histologically or cytologically confirmed adenocarcinoma of the prostate
- •De novo metastatic disease defined by clinical or radiographic evidence of metastases at diagnosis (i.e. before any treatment started). If not available, a more recent imaging can be used
- •Measurable disease or bone lesions evaluable according to PCWG3 criteria. Patients with doubtful metastases are not eligible
- •A pre-randomization 68Ga-PSMA-11 PET/CT scan performed within 4 weeks prior to randomization in the trial. FDG PET scan is not required for this protocol. All patients will be treated independently from the results of pre-randomization PSMA PET scan: patients with PSMA-positive or PSMA-negative disease according to PROMISE 2.0 criteria (see table below) are eligible.
- •Have 6 to 8 months of previous AND ongoing standard systemic treatment for prostate cancer at the time of signing the written informed consent form, consisting in either: • ADT with docetaxel* ± radiotherapy ** • ADT with an androgen receptor signaling inhibitor (ARSI) (i.e., abiraterone (plus prednisone), or apalutamide or darolutamide or enzalutamide) ± radiotherapy ** • ADT with docetaxel* plus an ARSI (i.e. abiraterone (plus prednisone), or darolutamide, or enzalutamide) ± radiotherapy** Note: *Docetaxel must have been stopped at least 4 weeks ahead of randomization. ** Previous radiotherapy to the primary tumor and/or to the metastases is accepted as long as it was not PSMA-based and must has been completed at least 4 weeks ahead of randomization.
排除标准
- •Any evidence of cancer progression (including a rising PSA level, clinical progression, or radiological progression)
- •Ongoing participation in another clinical trial involving an investigational product.. Treatment with any investigational product must have ended within 30 days prior to inclusion in the trial..
- •Patients unwilling or unable to comply with the medical follow-up required by the trial because of geographic, familial, social, or psychological reasons
- •Persons deprived of their liberty or under protective custody or guardianship
- •Prior or concurrent PSMA-based radioligand therapy or other PSMA target treatments
- •Known hypersensitivity to the components of the study therapy or its analogs
- •Any condition preventing the use of the standard of care and/or specific experimental treatments tested in the trial
- •Any of the following within 6 months before randomization: stroke, myocardial infraction, severe/unstable angina pectoris, coronary/peripheral artery bypass graft, congestive heart failure New York Heart Association (NYHA) Class III or IV
- •Hypertension not controlled by an anti-hypertensive treatment (systolic blood pressure [sBP] ≥ 160 mmHg or diastolic blood pressure [dBP] ≥ 95 mmHg)
- •Severe or uncontrolled concurrent disease, infection or co-morbidity
- •Pathological findings consistent with small cell carcinoma of the prostate
- •History of malignancy within the previous 3 years of inclusion with the exception of successfully treated basal or squamous cell skin carcinoma
结局指标
主要结局
Overall Survival (OS) is defined as the time from the date of randomization to the date of death due to any cause. Patients still alive at time of the analysis will be censored at the date of last news.
Overall Survival (OS) is defined as the time from the date of randomization to the date of death due to any cause. Patients still alive at time of the analysis will be censored at the date of last news.
Radiographic Progression-free survival (rPFS) is defined as the time from randomization to the date of radiographic progression according to PCWG3 criteria by investigator assessment, or death, whichever occurs first. In absence of radiographic progression or death, the data will be censored at the date of the last PCWG3 radiographic assessment.
Radiographic Progression-free survival (rPFS) is defined as the time from randomization to the date of radiographic progression according to PCWG3 criteria by investigator assessment, or death, whichever occurs first. In absence of radiographic progression or death, the data will be censored at the date of the last PCWG3 radiographic assessment.
次要结局
- Efficacy_Castration-Resistance Prostate Cancer-Free Survival (CRPC-FS) is defined as the time from randomization to the onset of castration-resistant prostate cancer or death from any cause, whichever occurs first. In absence of castration-resistance or death, the data will be censored at the date of the last PCWG3 assessment (minimum date PSA/imaging).
- Efficacy_Prostate cancer-specific survival (PCSS) is defined as the time from the date of randomization to the date of death due to prostate cancer. Death due to another cause than prostate cancer will be censored at the date of death. Patients still alive at time of the analysis will be censored at the date of last news.
- Efficacy_PSA response will be assessed by the maximum change of PSA (rise or fall) from baseline over the treatment period. A complete PSA response is defined by an undetectable level of serum PSA.
- Efficacy_Skeletal-related event-free survival (SRE-FS) is defined as the time from the randomization date to the date of diagnosis of either an SRE (fracture, or a bone pain requiring radiation therapy, or a spinal cord compression, or a preventive surgery to the bones) or death, whichever occurs first. Events will be evaluated by the investigators. No systematic X-Ray will be performed. In absence of SRE or death, data will be censored at the date of last news.
- Efficacy_Time to severe urinary event (SUE) is defined as the time from the randomization date to the date of diagnosis of either one of the following SUE, whichever occurs first: urinary retention with need for a urinary catheter, suprapubic catheter, double J stent, nephrostomy, treatment of the prostate by radiotherapy or trans-urethral resection of the prostate or prostatectomy done to relieve patients with local symptoms. In absence of SUE, data will be censored at the date of last news.
- Efficacy_Time to initiation of subsequent(first and second)anti-cancer systemic therapy for CRPC(TTSST1 and TTSST2).TTSST1 is defined as the time from randomization date to the date of initiation of first anti-cancer systemic therapy for CRPC.TTSST2 is defined as the time from the randomization date to the date of initiation of the second anti-cancer systemic therapy for CRPC. In absence of initiation of a subsequent anti-cancer systemic therapy, data will be censored at the date of last news
- Efficacy of subsequent (first and second) anti-cancer systemic therapy for CRPC will be assessed by either PSA response or rPFS, or OS and will be defined as the time from first and second anti-cancer systemic therapy for CRPC to disease progression or death from any cause, whichever comes first.
- Efficacy_Quality of Life (QoL) will be evaluated using the Brief Pain Inventory-Short Form (BPI-SF) and the Functional Assessment of Cancer Therapy-Prostate (FACT-P) questionnaire.
- Safety_Toxicity will be evaluated according to NCI-CTCAE v5.0.
- Exploratory_Biomarkers assessment to identify molecular characteristics and genetic or phenotypic abnormalities to correlate with disease outcome.
- Exploratory_Early PSMA PET evaluation and correlation between PSA and PSMA uptake variation will be assessed at 3 months (after cycle 2) according to PROMISE 2.0 criteria. In case of progression detected at early PSMA PET scan, it would not be considered for stopping treatment.
- Exploratory_Identification of PSMA PET imaging biomarkers to predict response and disease outcome will be assessed at pre-randomization based on semiquantitative analysis and total tumoral volume expressing PSMA.
- Exploratory_Radiation dosimetry of tumor tissues and normal organs (notably in salivary gland, bone marrow and kidney) to predict response and toxicity respectively will be perfomed on post-therapeutic images performed after the first cycle of 177Lu PSMA-617 (at least at 4 hours for output patients or 4 hours and 24 hours and Day 5 in case of hospitalization)._
研究者
Director of Regulatory Affairs, Quality and Pharmacovigilance
Scientific
Unicancer
研究点 (24)
Loading locations...
相似试验
招募中
2 期
A Phase I/II Study of Neoadjuvant, Intra-arterial Administration of [177Lu]Lu-PSMA-617 in Subjects with High-risk, Localised or Locally Advanced Prostate Cancer who are Candidates for Radical Prostatectomy (LUPUS)2022-500838-28-00Universitaetsklinikum Essen AöR22
招募中
2 期
68Ga/177Lu-PSMA theranostics in recurrent grade 3 and grade 4 glioma2024-518495-31-00Norwegian University Of Science And Technolology10
招募中
2 期
Radiometabolic Therapy (RMT) with 177Lu PSMA in PSMA PET/CT positive advanced/metastatic tumours: a basket trial (LUBASKET)2024-519346-75-00Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori IRST S.r.l.83
招募中
2 期
177Lu-PSMA as a systemic adjuvant treatment in patients with high and very high risk prostate cancer after radical treatment with locoregional teleradiotherapy and hormone therapy.Prostate Cancer2023-504912-13-00Narodowy Instytut Onkologii Im. Marii Sklodowskiej-Curie-Panstwowy Instytut Badawczy200
招募中
1/2 期
DUET-study: A FEASIBILITY STUDY OF 177LU-PSMA RADIOLIGAND THERAPY ALTERNATED WITH RADIUM-223 IN PATIENTS WITH BONE-METASTATIC, OLIGO-METASTATIC HORMONE-SENSITIVE PROSTATE CANCER AFTER CURATIVE THERAPY.Prostate cancer2024-518985-29-02Amsterdam UMC Stichting, Bayer B.V.6